SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-304491
Filing Date
2020-11-27
Accepted
2020-11-27 13:50:01
Documents
13
Period of Report
2020-11-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d93830d8k.htm   iXBRL 8-K 28621
2 EX-99.1 d93830dex991.htm EX-99.1 164932
  Complete submission text file 0001193125-20-304491.txt   360587

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20201124.xsd EX-101.SCH 3068
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20201124_lab.xml EX-101.LAB 17375
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20201124_pre.xml EX-101.PRE 10952
6 EXTRACTED XBRL INSTANCE DOCUMENT d93830d8k_htm.xml XML 3238
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 201354522
SIC: 2834 Pharmaceutical Preparations